Expertise in
6
conditions

Dr. Mark Mogul

Hematology | Oncology
Arnold Palmer Hospital Haley Center For Children's Cancer And Blood Disorders
92 W Miller St Fl 2, 
Orlando, FL 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Expertise in
6
conditions
Arnold Palmer Hospital Haley Center For Children's Cancer And Blood Disorders
92 W Miller St Fl 2, 
Orlando, FL 

Overview

Mark Mogul is a Hematologist and an Oncologist in Orlando, Florida. Dr. Mogul is highly rated in 6 conditions, according to our data. His top areas of expertise are Langerhans Cell Histiocytosis, Ependymoma, Histiocytosis, Reticulohistiocytoma, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 5 peer reviewed articles and participating in 50 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology
Oncology

Licenses

Pediatrics in CA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
View 2 Less Insurance Carriers -

Locations

Arnold Palmer Hospital Haley Center for Children's Cancer and Blood Disorders
92 W Miller St Fl 2, Orlando, FL 32806
Other Locations
Sierra Nevada Memorial Hospital
155 Glasson Way, Grass Valley, CA 95945

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

50 Clinical Trials

A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
Enrollment Status: Recruiting
Publish Date: April 07, 2026
Intervention Type: Procedure, Biological, Drug, Other
Study Drugs: Bleomycin, Bleomycin Sulfate, Carboplatin, Cisplatin, Etoposide, Etoposide Phosphate
Study Phase: Phase 3
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Enrollment Status: Active_not_recruiting
Publish Date: April 14, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Ensartinib, Erdafitinib, Larotrectinib, Olaparib, Palbociclib, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib
Study Phase: Phase 2
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Doxorubicin, Ifosfamide, Pazopanib
Study Phase: Phase 2/Phase 3
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Procedure, Biological, Radiation
Study Drugs: Cyclophosphamide, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, Ganitumab, Ifosfamide, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
A Phase 2 Study of the MEK Inhibitor Trametinib (NSC# 763093) in Children With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
A Phase 2 Study of the MEK Inhibitor Trametinib (NSC# 763093) in Children With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Drug
Study Drug: Trametinib
Study Phase: Phase 2
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Radiation, Drug, Biological, Other
Study Drugs: Cyclophosphamide, Dactinomycin, Irinotecan hydrochloride, Temsirolimus, Vincristine sulfate, Vinorelbine
Study Phase: Phase 3
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Other, Drug
Study Drug: Ensartinib
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex
Enrollment Status: Completed
Publish Date: April 13, 2026
Intervention Type: Drug
Study Drug: Tazemetostat
Study Phase: Phase 2
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Drug, Biological
Study Drugs: Bleomycin, Brentuximab, Cyclophosphamide, Doxorubicin, Etoposide, Methylprednisolone, Prednisone, Vincristine
Study Phase: Phase 3
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Enrollment Status: Completed
Publish Date: April 08, 2026
Intervention Type: Drug, Behavioral, Other, Procedure
Study Drug: 6-Mercaptopurine
Study Phase: Phase 3
View 9 Less Clinical Trials

5 Total Publications

Genomic stability at the coding regions of the multidrug transporter gene ABCB1: insights into the development of alternative drug resistance mechanisms in human leukemia cells.
Genomic stability at the coding regions of the multidrug transporter gene ABCB1: insights into the development of alternative drug resistance mechanisms in human leukemia cells.
Journal: Cancer drug resistance (Alhambra, Calif.)
Published: January 01, 2020
Similar Doctors
Expertise in
14
conditions
Dr. Don Eslin
Hematology | Oncology
Expertise in
14
conditions
Dr. Don Eslin
Hematology | Oncology

Orlando Health Arnold Palmer Hospital For Children

92 W Miller St, 
Orlando, FL 
 (0.1 miles away)
407-841-5111
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Don Eslin is a Hematologist and an Oncologist in Orlando, Florida. Dr. Eslin is highly rated in 14 conditions, according to our data. His top areas of expertise are Embryonal Tumor with Multilayered Rosettes, Neuroblastoma, Medulloblastoma, Glioma, and Bone Marrow Aspiration.

Expertise in
12
conditions
Dr. Juan Varela
Hematology | Oncology
Expertise in
12
conditions
Dr. Juan Varela
Hematology | Oncology

Orlando Health Scripts

1400 S Orange Ave, 
Orlando, FL 
 (0.2 miles away)
321-843-8010
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Juan Varela is a Hematologist and an Oncologist in Orlando, Florida. Dr. Varela is highly rated in 12 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Acute Myeloblastic Leukemia with Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
20
conditions
Dr. Guru Sonpavde
Oncology
Expertise in
20
conditions
Dr. Guru Sonpavde
Oncology

AHMG Oncology And Hematology At Orlando

2501 N Orange Ave Ste 689, 
Orlando, FL 
 (3.9 miles away)
321-732-5395
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Guru Sonpavde is an Oncologist in Orlando, Florida. Dr. Sonpavde is highly rated in 20 conditions, according to our data. His top areas of expertise are Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Orchiectomy, and Nephrectomy. Dr. Sonpavde is currently accepting new patients.

Frequently Asked Questions about Dr. Mark Mogul

How do I make an appointment with Dr. Mark Mogul?

You can book an appointment with Dr. Mark Mogul by calling their office at 321-841-8588. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mark Mogul a top-rated expert for Langerhans Cell Histiocytosis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mark Mogul is classified as an Advanced expert for Langerhans Cell Histiocytosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mark Mogul specialize in?

While Dr. Mark Mogul is a Hematology, they have specific expertise in Langerhans Cell Histiocytosis, Ependymoma, and Histiocytosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Mark Mogul participate in research or clinical trials?

Yes. Dr. Mark Mogul has published 5 articles and abstracts on conditions like Langerhans Cell Histiocytosis. You can view a list of Dr. Mark Mogul's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mark Mogul accept my insurance?

Dr. Mark Mogul accepts most major insurance plans, including Anthem BCBS and Blue Cross Blue Shield. We recommend calling the office directly at 321-841-8588 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mogul's expertise for a condition
ConditionClose
      View All 23 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile